CDK4/6 inhibitors in invasive lobular carcinoma: Efficacy, resistance patterns, and endocrine partners
Journal of Oncology Pharmacy Practice
Published online on March 24, 2026
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
BackgroundBreast cancer (BC) remains the most common malignancy in women, with 10–15% being invasive lobular carcinoma (ILC). ILC is typically estrogen receptor (ER) positive, slow-growing, and characterized by multicentricity, multifocality, bilateral ...
BackgroundBreast cancer (BC) remains the most common malignancy in women, with 10–15% being invasive lobular carcinoma (ILC). ILC is typically estrogen receptor (ER) positive, slow-growing, and characterized by multicentricity, multifocality, bilateral ...